临床静止期SLE患者撤减小剂量泼尼松的随机对照试验
结果显示维持组复发比例显著低于撤药组(4例 vs 17例),且至首次复发时间、轻中度复发及中重度复发均优于撤药组,而损伤指数增加与不良事件两组相似。
要点
- 临床静止期SLE患者继续维持5 mg/d泼尼松可显著降低52周复发风险。
- 维持组至首次复发时间显著延长,轻中度和中重度复发均减少。
- 两组SLICC损伤指数增加与不良事件相似,亚组分析未见疗效异质性。
核心结论
- 对临床静止期SLE患者,长期维持5 mg/d泼尼松可预防复发。
研究设计与样本
- 单中心、12个月、优效性、开放标签、随机(1:1)对照试验,61例继续5 mg/d泼尼松,63例撤药。
主要发现
- 维持组发生复发4例,撤药组17例,RR 0.2(95%CI 0.1至0.7),p=0.003。
- 维持组至首次复发时间更优,HR 0.2(95%CI 0.1至0.6),p=0.002。
- SFI轻中度复发维持组3例 vs 撤药组12例,RR 0.2(95%CI 0.1至0.8),p=0.012。
- BILAG中重度复发维持组1例 vs 撤药组8例,RR 0.1(95%CI 0.1至0.9),p=0.013。
- SDI增加与不良事件两组相似,预设基线特征亚组分析未显示临床反应差异。
关键数值与推荐
- 主要终点为52周时依据SELENA-SLEDAI复发指数(SFI)定义的复发患者比例。
- 入组条件为纳入前一年内临床无活动且SLE治疗稳定,包括5 mg/d泼尼松。
临床怎么用
- 对临床静止期超过1年且已稳定使用5 mg/d泼尼松的SLE患者,维持该剂量可能有助于减少复发。
局限性
- 单中心、开放标签设计可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the efficacy to prevent flares of maintenance versus withdrawal of 5 mg/day prednisone in systemic lupus erythematosus (SLE) patients with clinically quiescent disease. METHODS: A monocentric, 12-month, superiority, open-label, randomised (1:1) controlled trial was conducted with 61 patients continuing 5 mg/day prednisone and 63 stopping it. Eligibility criteria were SLE patients who, during the year preceding the inclusion, had a clinically inactive disease and a stable SLE treatment including 5 mg/day prednisone. The primary endpoint was the proportion of patient experiencing a flare defined with the SELENA-SLEDAI flare index (SFI) at 52 weeks. Secondary endpoints included time to flare, flare severity according to SFI and British Isles Lupus Assessment Group (BILAG) index and increase in the Systemic Lupus International Collaborating Clinics (SLICC) damage index (SDI). RESULTS: Proportion of patients experiencing a flare was significantly lower in the maintenance group as compared with the withdrawal group (4 patients vs 17; RR 0.2 (95% CI 0.1 to 0.7), p=0.003). Maintenance of 5 mg prednisone was superior with respect to time to first flare (HR 0.2; 95% CI 0.1 to 0.6, p=0.002), occurrence of mild/moderate flares using the SFI (3 patients vs 12; RR 0.2 (95% CI 0.1 to 0.8), p=0.012) and occurrence of moderate/severe flares using the BILAG index (1 patient vs 8; RR 0.1 (95% CI 0.1 to 0.9), p=0.013). SDI increase and adverse events were similar in the two treatment groups. Subgroup analyses of the primary endpoint by predefined baseline characteristics did not show evidence of a different clinical response. CONCLUSION: Maintenance of long term 5 mg prednisone in SLE patients with inactive disease prevents relapse. TRIAL REGISTRATION NUMBER: NCT02558517; Results.
引用
- Mathian A, Pha M, Haroche J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis. 2019. PMID: 31852672. doi:10.1136/annrheumdis-2019-216303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。